Renal Business Today

Roche

Drug-Maker Roche Buys Medingo Unit

Swiss drug-maker Roche Holding AG announced today that it bought Elron Electronics' Medingo unit in a deal worth up to $200 million, according to Reuters. ...More
April 13, 2010
Posted in News, Business, Clinical & Pharma
Study: Roche’s Weekly Diabetes Drug Cuts Blood Sugar

Roche announced results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose compared to other diabetes treatment options. Taspoglutide, the first weekly human GLP-1 analog in late stage ...More
February 12, 2010
Posted in News, Business, Clinical & Pharma
Roche Could Start Selling Mircera in U.S. in mid-2014

THOUSAND OAKS, Calif.—Roche could be able to market its anemia drug Mircera in the United States in mid-2014 after it admitted that it infringed on rival Amgen’s patents, according to a Dec. 22 news release from Amgen. ...More
December 22, 2009
Posted in News, Business, Clinical & Pharma, Government & Regulation
U.S Court Keeps Ban on Roche’s Anemia Drug Mircera

WASHINGTON— The U.S. Court of Appeals for the Federal Circuit on Tuesday upheld a ban on the sale of Roche’s anemia drug Mircera in the United States. ...More
September 15, 2009
Posted in News, Business, Clinical & Pharma
FDA Gives Roche Transplant Drug Anemia Warning

WASHINGTON—The U.S. Food and Drug Administration has placed a new warning on a Roche transplant drug about a type of anemia seen in some patients using the drug, according to a story by Reuters. ...More
August 19, 2009
Posted in News, Business, Clinical & Pharma
Top 10 Renal Stories of 2008

Years come and years go, but 2008 will long be remembered as the year that shaped the renal community for the 21st century. It was the year that the End-Stage Renal Disease Program saw some of its biggest changes in three decades, from the updated Conditions for Coverage as ...More
December 2, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation, Practice Management
Appeals court bars Roche from selling Mircera in U.S.

THOUSAND OAKS, Calif.—In what could be the death knell for Roche’s chances to break into the U.S. anemia market, a federal court of appeals upheld a preliminary injunction that effectively bars the sale of Mircera in the United States, according to Amgen. ...More
October 10, 2008
Posted in News, Business, Clinical & Pharma
Judge upholds injunction against Roche’s Mircera

BOSTON—A federal judge on Oct. 2 upheld a prior jury verdict reaffirming Amgen’s anemia drug patents and ruled that rival Roche should be barred from selling its anemia drug Mircera in the United States, according to a news release. ...More
October 3, 2008
Posted in News, Business, Clinical & Pharma
Amgen Still Owns the Power

IS THE ESRD PROVIDER community trapped in a flawed delivery system that benefits a few large organizations at the expense of the small dialysis provider? Given that Amgen has the power to unilaterally set pricing for Epogen (EPO), the question is, will Amgen ever level the ...More
May 1, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation
Amgen says no to Roche’s royalty offer

ZURICH—Amgen Inc. rejected Roche’s offer to pay a licensing fee so it could launch the rival anemia drug Mircera in the United States, according to a report by Thomas Financial. Roche offered to pay Amgen approximately 20 percent of new U.S. Mircera sales while Amgen’s ...More
March 20, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation